Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Intervalo de año de publicación
1.
An. bras. dermatol ; 97(2): 157-165, Mar.-Apr. 2022. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1374232

RESUMEN

Abstract Background Several treatments are available for skin with advanced photodamage, which is characterized by the presence of actinic keratoses (AK). Objectives Evaluate the efficacy of using sunscreen with photolyase compared to regular sunscreen, as well as to compare the combination of a topical formulation of antioxidants versus placebo in the treatment of advanced photodamage. Methods This was a randomized, double-blind, factorial clinical trial. Participants with AKs on their forearms were randomized to apply regular sunscreen (SC) or sunscreen with photolyase (SC+P) on both forearms during the day. One of the forearms in each group was randomized again to receive topical antioxidants (AOx), and the other forearm received a placebo cream (both for night application). The four groups were SC/AOx, SC/placebo, SC+P/AOx, and SC+P/placebo. The duration of treatment was 8 weeks. Primary outcomes were total AK clearance, decrease in Forearm Photoaging Scale (FPS), and AK severity scores. Secondary outcomes were reduction in AK count, partial clearance rate, and safety. Results Forty participants (80 forearms) were included. All groups showed significant improvement in outcomes at week eight. There were no significant differences between SC and SC+P for either outcome. AOx led to a significant reduction in AK count (22%; p < 0.05). Partial clearance was obtained in 18 (47.4%) forearms treated with AOx and in 9 (23.7%) treated with placebo (p < 0.05). All groups reduced the FPS score, without significant differences among them. Conclusions There is no difference in the treatment of advanced photodamage skin when comparing the use of sunscreen with photolyase and regular sunscreen, and topical antioxidants were more efficient in reducing AK count than placebo. Study limitations Short interval of follow-up and absence of re-evaluation in the absence of treatment were limitations of the present study.

2.
An Bras Dermatol ; 97(2): 157-165, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35039206

RESUMEN

BACKGROUND: Several treatments are available for skin with advanced photodamage, which is characterized by the presence of actinic keratoses (AK). OBJECTIVES: Evaluate the efficacy of using sunscreen with photolyase compared to regular sunscreen, as well as to compare the combination of a topical formulation of antioxidants versus placebo in the treatment of advanced photodamage. METHODS: This was a randomized, double-blind, factorial clinical trial. Participants with AKs on their forearms were randomized to apply regular sunscreen (SC) or sunscreen with photolyase (SC+P) on both forearms during the day. One of the forearms in each group was randomized again to receive topical antioxidants (AOx), and the other forearm received a placebo cream (both for night application). The four groups were SC/AOx, SC/placebo, SC+P/AOx, and SC+P/placebo. The duration of treatment was 8 weeks. Primary outcomes were total AK clearance, decrease in Forearm Photoaging Scale (FPS), and AK severity scores. Secondary outcomes were reduction in AK count, partial clearance rate, and safety. RESULTS: Forty participants (80 forearms) were included. All groups showed significant improvement in outcomes at week eight. There were no significant differences between SC and SC+P for either outcome. AOx led to a significant reduction in AK count (22%; p < 0.05). Partial clearance was obtained in 18 (47.4%) forearms treated with AOx and in 9 (23.7%) treated with placebo (p < 0.05). All groups reduced the FPS score, without significant differences among them. CONCLUSIONS: There is no difference in the treatment of advanced photodamage skin when comparing the use of sunscreen with photolyase and regular sunscreen, and topical antioxidants were more efficient in reducing AK count than placebo. STUDY LIMITATIONS: Short interval of follow-up and absence of re-evaluation in the absence of treatment were limitations of the present study.


Asunto(s)
Desoxirribodipirimidina Fotoliasa , Queratosis Actínica , Antioxidantes/uso terapéutico , Desoxirribodipirimidina Fotoliasa/uso terapéutico , Humanos , Queratosis Actínica/tratamiento farmacológico , Protectores Solares/uso terapéutico , Resultado del Tratamiento
3.
Surg. cosmet. dermatol. (Impr.) ; 14: e20220119, jan.-dez. 2022.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1391139

RESUMEN

Cisto veloso eruptivo é condição dermatológica rara e benigna do desenvolvimento dos folículos pilosos do tipo vellus, que acomete principalmente crianças e adultos jovens, e se caracteriza por múltiplas pápulas assintomáticas, especialmente no tronco. Apresentamos o caso de um homem adulto, de 33 anos, branco, que apresentava múltiplas pápulas eritematosas e pústulas, localizadas no tronco há cerca de cinco anos, refratárias a tratamentos tópicos para acne. A dermatoscopia revelou lesões ovaladas, com exulceração excêntrica e raras estruturas filiformes acrômicas protrusas do seu interior. Estabeleceu-se o diagnóstico de cisto veloso eruptivo a partir dos achados da dermatoscopia e do exame histopatológico


Eruptive vellus hair cyst is a rare and benign dermatological condition in the development of vellus-type hair follicles. It affects mainly children and young adults, and is characterized by multiple asymptomatic papules, especially on the trunk. We report the case of a 33-year-old white man who presented multiple erythematous papules and pustules located on the trunk for about five years, refractory to topical treatments for acne. Dermoscopy revealed oval lesions with eccentric exulceration and rare protruding filiform structures. We established the diagnosis of eruptive vellus hair cyst based on the findings of dermoscopy and histopathological examination.

4.
An Bras Dermatol ; 95(6): 740-742, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32912801

RESUMEN

Paracoccidoiomycosis is a systemic mycosis with a higher incidence in males with history of exposure to the rural environment; its classic clinical manifestation is an oro-pulmonary lesion. The authors report a case of a female, urban, 76-year-old patient with atypical clinical-dermatological presentation and diagnostic conclusion after histopathological examination. The clinical response was quick and complete after treatment with itraconazole 400mg/day in the first month, decreased to 200mg/day until the sixth month of treatment.


Asunto(s)
Paracoccidioidomicosis , Anciano , Antifúngicos/uso terapéutico , Femenino , Humanos , Itraconazol/uso terapéutico , Pulmón , Masculino , Paracoccidioidomicosis/diagnóstico , Paracoccidioidomicosis/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...